Moleculin Biotech, Inc. (MBRX) stock
MBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.75−0.08 (-1.17%)
Close on Nov 18, 2026Market cap $131.47MP/E –Yield –
Moleculin Biotech operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Moleculin Biotech's operating income for the twelve months ending Jun 30, 2026 was -$28.87M. For fiscal 2025 it was -$25.10M. The highest annual figure on record is -$3.88M in fiscal 2016.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$25.10M | – |
| FY2024 | Dec 31, 2024 | -$26.64M | – |
| FY2023 | Dec 31, 2023 | -$29.63M | – |
| FY2022 | Dec 31, 2022 | -$30.64M | – |
| FY2021 | Dec 31, 2021 | -$22.97M | – |
| FY2020 | Dec 31, 2020 | -$19.74M | – |
| FY2019 | Dec 31, 2019 | -$17.52M | – |
| FY2018 | Dec 31, 2018 | -$15.03M | – |
| FY2017 | Dec 31, 2017 | -$8.65M | – |
| FY2016 | Dec 31, 2016 | -$3.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.87M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.53M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.72M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.94M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.64M | – |
| Q3 FY2024 | Sep 30, 2024 | -$7.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.68M | – |
| Q4 FY2023 | Dec 31, 2023 | -$8.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.95M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.05M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.08M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.43M | – |
| Q1 FY2022 | Mar 31, 2022 | -$7.07M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$6.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.52M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.09M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.50M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.15M | – |
| Q2 FY2020 | Jun 30, 2020 | -$5.03M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$4.81M | – |
| Q3 FY2019 | Sep 30, 2019 | -$4.51M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.63M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.57M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.34M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.59M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.46M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.64M | – |
| Q4 FY2017 | Dec 31, 2017 | -$3.39M | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.40M | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.42M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.42M | – |
| Q2 FY2016 | Jun 30, 2016 | -$724.00K | – |
See a number that looks wrong?